Skip Navigation

European Heart Journal 2004 25(1):96-97; doi:10.1016/j.ehj.2003.06.011
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mickley, H.
Right arrow Articles by Bøtker, H. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mickley, H.
Right arrow Articles by Bøtker, H. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letter to the Editor

Is an additional post-myocardial infarction ß-blocker trial required in the era of early revascularization?

Hans Mickleya,*, Hans Eiskjærb and Hans Erik Bøtkerc

a Odense University Hospital, Odense, Denmark
b Aarhus University Hospital, Skejby, Denmark
c Aarhus University Hospital, Skejby, Denmark

* Corresponding author: Hans Mickley, MD, Ph.D., Department of Cardiology, Odense University Hospital, 5000 Odense C, Denmark. Tel.: +4565411894
E-mail address: hans.mickley@dadlnet.dk

Received 17 February 2003; revised 9 April 2003; accepted 20 June 2003

The first 10% of the full text of this article appears below.

The new guidelines addressing the management of patients with acute coronary syndromes have recently been published.1,2These guidelines are the first in Europe after the redefinition of acute myocardial infarction (AMI). Treatment strategies in the early phase of AMI have changed dramatically during the last 10–15 years. However, the evidence that confirms a prognostic . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
J. N. Rasmussen, A. Chong, and D. A. Alter
Relationship Between Adherence to Evidence-Based Pharmacotherapy and Long-term Mortality After Acute Myocardial Infarction
JAMA, January 10, 2007; 297(2): 177 - 186.
[Abstract] [Full Text] [PDF]